Johnson & Johnson
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +10.53%.
Did JNJ Beat Earnings? Q1 2025 Results
Johnson & Johnson opened 2025 with a convincing beat across the board, posting first-quarter adjusted EPS of $2.77 against a consensus of $2.58 — a 7.34% beat — while revenue of $21.89 billion edged past estimates by 1.48% and grew 2.4% year-over-year. The headline driver was a surging oncology franchise within Innovative Medicine, where DARZALEX alone contributed $3.24 billion in sales, up 20.3%, helping offset an approximately 810 basis point headwind from STELARA biosimilar erosion. MedTech added $8.02 billion, lifted by cardiovascular strength including the newly acquired Shockwave platform. For investors <a href="https://247wallst.com/investing/2025/07/16/johnson-johnson-nyse-jnj-live-earnings-updates-will-the-dividend-champion-deliver/">watching the dividend champion closely</a>, J&J also announced a 4.8% dividend increase — its 63rd consecutive year of raises — alongside a commitment to more than $55 billion in U.S. investment. Looking ahead, the company maintained its adjusted EPS guidance of $10.50–$10.70 for full-year 2025, absorbing tariff costs and acquisition dilution while integrating Intra-Cellular Therapies' CAPLYTA into its growing neuroscience portfolio.
- DARZALEX worldwide sales grew 20.3% to $3.2B driven by strong demand in oncology
- CARVYKTI worldwide sales more than doubled to $369M
- TREMFYA grew 18.2% to $956M with Crohn's disease approval expanding addressable market
- SPRAVATO grew 41.9% to $320M in neuroscience
- XARELTO grew 33.3% to $690M in cardiovascular
- MedTech Cardiovascular grew 16.4% driven by Abiomed and Shockwave acquisition
- STELARA declined 33.7% to $1.6B representing ~810 basis points headwind from biosimilar competition
- U.S. sales grew 5.9% while international declined 1.8% due to currency headwinds
“The power of Johnson & Johnson's uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance.”
Johnson & Johnson CEO, on the earnings call
Forward Guidance & Outlook
J&J updated full-year 2025 guidance: adjusted operational sales growth of 2.0%–3.0% (midpoint 2.5%), operational sales of $91.6B–$92.4B (midpoint $92.0B, 3.3%–4.3% growth), estimated reported sales of $91.0B–$91.8B (midpoint $91.4B, 2.6%–3.6% growth). Adjusted operational EPS (diluted) of $10.50–$10.70 (midpoint $10.60, 5.2%–7.2% growth). Adjusted reported EPS (diluted) of $10.50–$10.70 (midpoint $10.60, 5.2%–7.2% growth). The guidance increase to operational sales reflects the addition of CAPLYTA following the Intra-Cellular Therapies acquisition. The company maintained its adjusted EPS outlook despite absorbing tariff costs, acquisition dilution, and updated foreign exchange headwinds.
JNJ YoY Financials
JNJ Revenue by Segment
JNJ Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.